Orchard Therapeutics PE Ratio 2017-2021 | ORTX

Current and historical p/e ratio for Orchard Therapeutics (ORTX) from 2017 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Orchard Therapeutics PE ratio as of September 23, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Orchard Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-09-23 2.58 0.00
2021-06-30 4.39 $-1.14 0.00
2021-03-31 7.26 $-1.33 0.00
2020-12-31 4.32 $-1.53 0.00
2020-09-30 4.11 $-1.65 0.00
2020-06-30 6.00 $-1.83 0.00
2020-03-31 7.53 $-1.91 0.00
2019-12-31 13.75 $-1.75 0.00
2019-09-30 11.88 $-1.29 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.302B $0.003B
Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based in London, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71